𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combination therapy with sorafenib and S-1 for renal cell carcinoma producing granulocyte colony-stimulating factor

✍ Scribed by Yoko Kyono; Tatsuya Takayama; Mana Kinoshita; Yutaka Kurita; Soichi Mugiya; Satoshi Baba; Seiichiro Ozono

Publisher
Springer
Year
2010
Tongue
English
Weight
515 KB
Volume
16
Category
Article
ISSN
1341-9625

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Granulocyte-macrophage–colony stimulatin
Granulocyte-macrophage–colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma : Results of two Phase II clinical trials
✍ Christopher W. Ryan; Nicholas J. Vogelzang; Mary C. Dumas; Timothy Kuzel; Walter πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 94 KB πŸ‘ 2 views

The aim of this study was to determine the response rates and toxicity of two regimens containing granulocyte-macrophage-colony stimulating factor (GM-CSF) in combination with interleukin-2 (IL-2) in the treatment of patients with metastatic renal cell carcinoma. ## METHODS. Therapy given in the f

Phase II trial of subcutaneously adminis
Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma
✍ Edward Wos; Thomas Olencki; Laurie Tuason; G. Thomas Budd; David Peereboom; Kate πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 465 KB πŸ‘ 2 views

## BACKGROUND. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine that is involved in the differentiation and proliferation of various hematopoietic precursors. It also has been reported to enhance the antitumor activity of various mature effector cells. Previous reports have